An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease
Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with pa...
Source: Signal Transduction Knowledge Environment - August 3, 2020 Category: Science Authors: Brubaker, D. K., Kumar, M. P., Chiswick, E. L., Gregg, C., Starchenko, A., Vega, P. N., Southard-Smith, A. N., Simmons, A. J., Scoville, E. A., Coburn, L. A., Wilson, K. T., Lau, K. S., Lauffenburger, D. A. Tags: STKE Research Articles Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Vedolizumab and Infliximab in UC After Failure of Anti-TNF Vedolizumab and Infliximab in UC After Failure of Anti-TNF
In this study, in patients with ulcerative colitis refractory to an anti-TNF agent, vedolizumab was more effective than infliximab in achieving clinical remission.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Biosimilar ABP 710 vs Infliximab Reference Product in RA Biosimilar ABP 710 vs Infliximab Reference Product in RA
Might this new biosimilar be a viable treatment option for patients with rheumatoid arthritis? How does it compare with infliximab reference product?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, C...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Determining Therapeutic Range of Anti-TNF Therapies in IBD Determining Therapeutic Range of Anti-TNF Therapies in IBD
This review describes the principles and process followed to define the target therapeutic ranges for infliximab and adalimumab in the treatment of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New UC Guidelines Preferentially Rank Biologics New UC Guidelines Preferentially Rank Biologics
New guidance for moderate to severe UC prioritizes early use of biologics after 5-ASA failure and preferentially ranks infliximab and golimumab as first-line options in biologic-na ï ve patients.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 4, 2020 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Ixifi (Infliximab-qbtx for Injection, for Intravenous Use ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 3, 2020 Category: Drugs & Pharmacology Source Type: news

Havertown Doctor Pleads Guilty to Unlawfully Importing Foreign, Injectable Drugs and Unlawfully Distributing Oxycodone
Thomas Whalen, Havertown PA, Guilty plea, importation, heath care fraud, oxycodone, D.O., controlled substance, Whalen Rheumatology Group, Exton PA, Wilmington DE, Unapproved, Injection, Infusion, Remicade Synvisc, Synvisc-One, Orencia, Prolia/Xgeva, Boniva (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - December 19, 2019 Category: Medical Law Authors: DOJ Source Type: news

Doctors warn Crohn's, arthritis patients will pay a price as Alberta pulls drug funding
Doctors say 2,000 patients in Alberta will pay a price with the government's plan to stop funding Remicade, a drug used to treat people with Crohn's and colitis. (Source: CBC | Health)
Source: CBC | Health - December 17, 2019 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news

Avsola (Infliximab-axxq for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 11, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen's Biosimilar to J & J's Rheumatoid Arthritis Drug FDA Approves Amgen's Biosimilar to J & J's Rheumatoid Arthritis Drug
The U.S. Food and Drug Administration on Friday approved Amgen Inc ' s biosimilar copy of Johnson& Johnson ' s blockbuster rheumatoid arthritis drug, Remicade, according to the regulator ' s website.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 10, 2019 Category: Orthopaedics Tags: Pharmacist News Source Type: news

FDA approves Amgen's biosimilar to J & J's rheumatoid arthritis drug
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson& Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 6, 2019 Category: Drugs & Pharmacology Source Type: news

Reimbursing infliximab for Crohn's disease cost effective in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2019 Category: Drugs & Pharmacology Source Type: news